Journal of Genetics and Genomes

Genomics technologies such as next-generation sequencing (NGS) and microarrays accelerate neurogenomics research by revealing the mechanisms behind complex neurological disorders such as Alzheimer’s, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders. The interaction between genetic and non-genetic mutations, epigenetics, and other factors requires an analysis of the NGS level to broaden our understanding. Arrays aids in major studies of a variety of genes related to neurological disorders. Illumina provides NGS and the same tools needed to make neurogenomics research possible.

Genomics technologies such as next-generation sequencing (NGS) and microarrays accelerate neurogenomics research by revealing the mechanisms behind complex neurological disorders such as Alzheimer’s, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders. The interaction between genetic and non-genetic mutations, epigenetics, and other factors requires an analysis of the NGS level to broaden our understanding. Arrays aids in major studies of a variety of genes related to neurological disorders. Illumina provides NGS and the same tools needed to make neurogenomics research possible.

Chromatin immunoprecipitation (ChIP) tests examine histone mutations and genomic DNA sequences bound to specific regulatory proteins. In ChIP, protein-DNA complexes are linked to in vivo, are immune, purified, and amplified for genetic targeting and developer of known targets or to identify new target sequences. In a microarray-based, ChIP-on-Chip, DNA immunoprecipitated DNA is labeled and packaged in high-resolution microarrays.